With a robust background in technology and healthcare investments, the fund manager has successfully navigated both early-stage and growth equity deals. Active across North America and Europe, they have closed over 30 transactions, showcasing a strategic focus on operator-first investments. Their track record includes notable exits in the biotech sector, reflecting a data-driven approach to identifying market trends. This experience equips them to leverage deep industry insights to enhance portfolio performance.